Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 376 of 5804
-
Self-Sampling could boost cervical cancer screening for women with HIV
Disease control Recruiting nowThe investigators propose to develop and/or adapt implementation strategies and a structured implementation plan to translate the HOPE intervention into existing healthcare practice in Ghana. These "implementation support strategies (ISS)" are implementation strategies relevant …
Phase: NA • Sponsor: Baylor University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill combo aims to crush bad cholesterol
Disease control OngoingResearchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to boost cervical cancer treatment
Disease control Recruiting nowThis study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Ca…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New immune-boosting combo targets stubborn lymphoma
Disease control Recruiting nowOpen Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo aims to reignite immune attack on tough childhood cancer
Disease control Recruiting nowThe study participant is being asked to take part in this research study because the participant has been diagnosed with neuroblastoma that did not fully respond to previous treatment (refractory), or it has returned after treatment (relapsed). Primary Aims * To evaluate if the…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could a chemo fog be the key to fighting ovarian cancer?
Disease control Recruiting nowEvaluation Compared with traditional NACT, whether PIPAC can increase the incidence of CRS3 determines the rationality of choosing PIPAC.
Phase: PHASE3 • Sponsor: tongweihua • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
AI reads laparoscopy videos to guide ovarian cancer surgery
Diagnosis Not yet recruitingThe standard treatment for advanced ovarian cancer (AOC) is primary cytoreductive surgery (PCS) followed by adjuvant chemotherapy. However, optimal cytoreduction is not always achievable, particularly in cases with high tumor burden or patient frailty. In such scenarios, neoadjuv…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
Engineered immune cells take on virus-driven cancers in early trial
Disease control Recruiting nowThis is a Phase 1/Phase 2 open-label, single-arm clinical study of GP350 CAR-T for Relapse/Refractory and Epstein-Barr virus infection associated lymphoid neoplasms. Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy, …
Phase: PHASE1, PHASE2 • Sponsor: Zhimin Zhai • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Heart valve showdown: open surgery vs. less invasive option – which is better?
Disease control Recruiting nowThe overall hypothesis is that redo aortic valve replacement (rAVR) is superior to valve-invalve transcatheter aortic valve replacement (ViV-TAVR) for the composite endpoint of freedom from all-cause mortality, all-cause stroke, myocardial infarction, and rehospitalization for he…
Phase: NA • Sponsor: Heart Center Leipzig - University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug aims to tame rare blood vessel disease
Disease control Recruiting nowThe primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combina…
Phase: PHASE3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot aims to save sight in advanced macular degeneration
Disease control Recruiting nowPhase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail of cancer drugs shows promise for Tough-to-Treat sarcoma
Disease control OngoingThis phase II/III trial compares the effect of vincristine, irinotecan, and regorafenib (VIrR) in combination with vincristine, doxorubicin, cyclophosphamide (VDC), ifosfamide and etoposide (IE) to usual treatment with VDC/IE for the treatment of newly diagnosed Ewing sarcoma or …
Phase: PHASE2, PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Chemo-Free hope: new combo before lung surgery shows promise
Disease control Not yet recruitingThe neoadjuvant strategy of immunotherapy combined with chemotherapy has been recommended for resectable or potentially resectable tumors without driver-gene alterations.However, the AE of chemotherapy is more than 40%,which bring fear to the patients,especially for those who can…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Organic veggies for pregnant women: a green prescription to cut pesticides?
Prevention Recruiting nowNumerous studies have highlighted the harmful effects of pesticide exposure during the prenatal period. Food is one of the main vectors of exposure to pesticides, particularly glyphosate, which is the most widely used herbicide. Observational studies have highlighted their effect…
Phase: NA • Sponsor: University Hospital, Strasbourg, France • Aim: Prevention
Last updated Jun 27, 2026 07:57 UTC
-
Can we stop these cancer drugs without the tumor coming back?
Disease control Recruiting nowThis phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking th…
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Brain zaps to beat booze: new trial tests magnetic therapy for alcoholism
Disease control Recruiting nowThe study will compare alcohol use in two groups of subjects. One group will be assigned to the Deep TMS treatment and the other group will be assigned to the sham treatment. This is a prospective, 6-month, double blind, randomized, controlled, multi-center trial in outpatients r…
Phase: NA • Sponsor: Brainsway • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Sound waves zap liver tumors in groundbreaking asian trial
Disease control Recruiting nowThe HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune…
Phase: NA • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can a common steroid save lives after severe burns?
Disease control Recruiting nowBurns affect more than 11 million people worldwide each year. These injuries are responsible for severe morbidity resulting in a high societal burden and account for more than 180,000 yearly deaths especially in low- and middle-income countries. Major burns induce an important l…
Phase: PHASE3 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Can a Cholesterol-Lowering shot reverse brain artery blockages?
Disease control Recruiting nowThis is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assess…
Phase: PHASE4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for Hard-to-Treat myeloma: QLS32015 enters phase 3 trial
Disease control Recruiting nowThe purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC